Dermatology Department, Pontevedra University Hospital, Pontevedra, Spain.
Medical Oncology Department, A Coruña University Hospital, A Coruña, Spain.
Int J Dermatol. 2021 Feb;60(2):208-216. doi: 10.1111/ijd.15081. Epub 2020 Aug 9.
Targeted therapies and immunotherapies are increasingly prescribed, but classic chemotherapy agents are still highly used in cancer treatment. Both therapies, the old and the new, are associated with cutaneous adverse events (CAEs) that can cause treatment interruptions or reduce the quality of life of patients.
An observational, cross-sectional, single-center study that included consecutive cancer patients presenting CAEs. The main objective was to describe CAEs derived from antineoplastic drugs. Secondary objectives were to determine the number and severity of CAEs and if there were differences regarding CAEs between conventional chemotherapeutics and targeted therapies.
A total of 114 patients were included with a total number of 177 CAEs. Of the 114 patients, 64 presented a single CAE, 37 patients had two CAEs, and 13 patients presented three CAEs. The most frequent CAEs were pruritus, xerosis, palmar-plantar erythrodysesthesia (PPE), and alopecia. The majority of CAEs were mild (63.2%), followed by moderate (29.9%) and severe (6.7%) CAEs. Of the 114 patients, 103 (90.3%) received topical agents and 11 (9.7%) required systemic treatment for the management of CAEs. Prophylactic treatment for CAE was delivered to only 4/114 (3.5%) patients. No significant differences were found in the number or severity of CAEs between conventional chemotherapy and targeted therapy.
Close collaboration between oncologists and dermatologists is essential to start preventive measures on time, enhance patient education, and avoid unnecessary dose reductions or treatment interruptions. The multidisciplinary approach can offer better management of skin toxicities.
靶向治疗和免疫疗法的应用日益增多，但经典的化疗药物在癌症治疗中仍被广泛使用。这两种疗法，无论是新的还是旧的，都与皮肤不良反应（CAEs）有关，这些不良反应可能导致治疗中断或降低患者的生活质量。
这是一项观察性、横断面、单中心研究，纳入了出现 CAEs 的连续癌症患者。主要目的是描述抗肿瘤药物引起的 CAEs。次要目标是确定 CAEs 的数量和严重程度，以及传统化疗药物和靶向治疗药物之间是否存在 CAEs 差异。
共纳入 114 例患者，共发生 177 例 CAEs。在 114 例患者中，64 例患者出现单个 CAE，37 例患者出现两个 CAE，13 例患者出现三个 CAE。最常见的 CAEs 是瘙痒、皮肤干燥、手掌-足底红斑感觉异常（PPE）和脱发。大多数 CAEs 为轻度（63.2%），其次是中度（29.9%）和重度（6.7%）。在 114 例患者中，103 例（90.3%）接受了局部药物治疗，11 例（9.7%）需要系统治疗来管理 CAEs。只有 4/114（3.5%）例患者接受了 CAE 预防治疗。在常规化疗和靶向治疗之间，CAEs 的数量或严重程度没有发现显著差异。
肿瘤学家和皮肤科医生之间的密切合作对于及时启动预防措施、加强患者教育以及避免不必要的剂量减少或治疗中断至关重要。多学科方法可以更好地管理皮肤毒性。
